Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elio Adib

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
JCO Precision Oncology|February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint InhibitorsCsaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2021
<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid TumorsElio Adib, Amin H Nassar, Elie W Akl, et al.
Blood Advances|November 30, 2021
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemiaSabrin Tahri, Tarek H Mouhieddine, Robert Redd, et al.
Cancer Cell|September 29, 2023
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistanceDonjeta Gjuka, Elio Adib, Kendra Garrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.
Cell Reports|March 31, 2021
Trans-ethnic variation in germline variants of patients with renal cell carcinomaSarah Abou Alaiwi, Amin H Nassar, Elio Adib, et al.
Clinical Genitourinary Cancer|July 20, 2024
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder CancerWilliam Paul Skelton, Jack Masur, Jonathan Thomas, et al.
Cancer|February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Jiaming Huang, Christian Mouchati, et al.
Molecular Cancer Research : MCR|February 24, 2026
Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular SubtypesElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
JCO Precision Oncology|February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint InhibitorsCsaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2021
<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid TumorsElio Adib, Amin H Nassar, Elie W Akl, et al.
Blood Advances|November 30, 2021
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemiaSabrin Tahri, Tarek H Mouhieddine, Robert Redd, et al.
Cancer Cell|September 29, 2023
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistanceDonjeta Gjuka, Elio Adib, Kendra Garrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.
Cell Reports|March 31, 2021
Trans-ethnic variation in germline variants of patients with renal cell carcinomaSarah Abou Alaiwi, Amin H Nassar, Elio Adib, et al.
Clinical Genitourinary Cancer|July 20, 2024
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder CancerWilliam Paul Skelton, Jack Masur, Jonathan Thomas, et al.
Cancer|February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Jiaming Huang, Christian Mouchati, et al.
Molecular Cancer Research : MCR|February 24, 2026
Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular SubtypesElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.
Pageof 5